BridgeBio Pharma is offloading its rare pediatric disease priority review voucher (PRV) for $110 million to an undisclosed buyer.
Source: Drug Industry Daily
BridgeBio Pharma is offloading its rare pediatric disease priority review voucher (PRV) for $110 million to an undisclosed buyer.
Source: Drug Industry Daily